Developer docs
API playgroundTry for free, no card

Search company profiles

Comac Medical

Full company profile

uuid000758f

Namestring
Comac Medical
Legal namestring
Comac Medical Ltd.
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) headquartered in Sofia, Bulgaria, delivering clinical trial services from Phase I through Phase IV, including post-marketing, medical device, nutraceutical, biosimilar, and generics studies. The company was founded in 1998 and operates across 24+ countries with 350+ employees, leveraging a fully owned, Europe-based Early Phase Clinical Research Unit and an in-house GCLP-accredited Bioanalytical Laboratory. Its customer base spans major pharmaceutical companies, biotechnology firms, and other CROs, and it is recognized as a Top 10 CRO in Europe.

The company's service portfolio is organized into integrated solutions and services covering early phase trials, late phase trials, post-marketing studies, medical devices and nutraceuticals, and biosimilars/generics, supported by a Functional Service Provider (FSP) offering for flexible resourcing. Comac monetizes through quote-based, project-priced professional services engagements on multi-year contracts, sold through a direct enterprise sales motion supplemented by heavy participation in industry conferences (OCT Europe, Swiss Biotech Day, BioEurope, ASCO, ESMO). Comac holds ISO 9001:2015 certification, GCLP laboratory accreditation, French Ministry R&D approval, and has received FDA No Action Indicated (NAI) inspection letters.

In June 2023, Edgecap acquired a majority stake while founder Milen Vrabevski and management retained a meaningful minority. The company has since professionalized its executive team, appointing a new Group CEO, CFO, COO, and CCO, and in June 2025 acquired ILIFE Consulting, a Paris-based specialty CRO focused on oncology, rare diseases, and complex biotech trials. The combined platform is positioned as a flexible, cost-efficient boutique alternative to large global CROs, with deep Central and Eastern European reach and growing Western European and US presence.

Short descriptiontext

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) headquartered in Bulgaria, delivering Phase I-IV clinical trials, bioanalytical, and FSP services to pharmaceutical, biotech, and CRO clients across 24+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSofia, Bulgaria
HQ citystring
Sofia
HQ countrystring
Bulgaria
HQ regionstring
Europe
Markets served

Serves global market

Offices14 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, contract research organization, early phase trials, functional service provider, biopharma clinical research
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Contract Research Organization (CRO) Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1CRO Services - Clinical Trial Management
TypeProfessional Services
Description

Full-service Contract Research Organization services managing clinical trials from Phase I through Phase IV, including project management, monitoring, data management, and regulatory affairs

comac-medical.com
2Early Phase Clinical Research Unit
TypeProfessional Services
Description

Dedicated early phase clinical trial unit providing first-in-human and proof-of-concept studies for pharmaceutical and biotech sponsors

comac-medical.com
3Functional Service Provider (FSP)
TypeManaged Services
Description

Flexible staffing and functional service solutions providing dedicated resources or functional support to sponsors

comac-medical.com
4Medical Devices & Nutraceuticals
TypeProfessional Services
Description

Clinical investigation services for medical devices and food supplements/nutraceuticals

comac-medical.com
5Biosimilar & Generics Development
TypeProfessional Services
Description

Clinical development services specifically designed for biosimilar and generic pharmaceutical products

comac-medical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Custom project-based pricing tailored to sponsor requirements
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available. Services are negotiated on a per-project basis based on scope, duration, phases, and specific requirements. Quote-based engagement model typical for enterprise CRO services.

comac-medical.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ILIFE Consulting
Description

Specialized CRO headquartered in Paris, France, renowned for expertise in oncology, rare diseases, and complex biotech clinical trials. Founded in 2013 by Marina Iché.

comac-medical.com
Core offering1 text field

Comac Medical is a full-service Pan-European Contract Research Organization (CRO) delivering clinical trial solutions from Phase I through Phase IV. Its offering spans early-phase clinical trials, late-phase trials, post-marketing trials, medical device and nutraceutical investigations, and biosimilar/generics development, supported by a Europe-based fully owned Early Phase Clinical Research Unit and in-house Bioanalytical Lab. It also provides Functional Service Provider (FSP) and dedicated resource/consulting services to pharmaceutical, biotech, and other CRO clients across 24+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Industry-leading speed in patient recruitment, site access, and retention
+3 more records
Product overview1 text field

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) offering an integrated portfolio of clinical trial solutions spanning early phase (Phase I-II), late phase (Phase III-IV), post-marketing trials, medical devices, and biosimilar/generics services. The core offering is organized around Solutions (Early Phase Clinical Trials, Late Phase Clinical Trials, Post Marketing Trials, Medical Devices & Nutraceuticals, Biosimilar & Generics) and Services (CRO Services, Early Phase Clinical Research Unit, and Functional Service Provider). The company also maintains a fully owned Europe-based Early Phase Unit and Bioanalytical Lab, supporting end-to-end trial delivery from a single platform.

Product and service8 records
1Early Phase Clinical Trials
CategoryEarly Phase Clinical Trials
Description

Comprehensive Phase I-II early phase clinical trial solutions leveraging a Europe-based fully owned Early Phase Unit and Bioanalytical Lab, tailored for biotech and complex clinical studies including oncology and rare diseases.

2Late Phase Clinical Trials
CategoryLate Phase Clinical Trials
Description

Full-service Phase III-IV late phase clinical trial management and execution across diverse European regions.

3Post Marketing Trials
CategoryPost-Marketing Trials
Description

Post-marketing surveillance and observational trial services supporting product lifecycle management.

4Medical Devices & Nutraceuticals
CategoryMedical Devices & Nutraceuticals
Description

Clinical investigation services for medical devices and food supplements, covering regulatory and execution needs.

5Biosimilar & Generics
CategoryBiosimilar & Generics Development
Description

Specialized clinical trial services for biosimilar and generic pharmaceutical products.

6Contract Research Organization (CRO) Services
CategoryCRO Services
Description

Full-service CRO services covering study design, project management, site monitoring, data management, and regulatory affairs across all trial phases.

7Early Phase Clinical Research Unit
CategoryEarly Phase Clinical Research
Description

Europe-based, fully owned early phase clinical research unit and bioanalytical laboratory, combining long-term expertise with cutting-edge facilities in one location; operates 2 Early Phase Unit locations.

8Functional Service Provider (FSP)
CategoryFunctional Service Provider
Description

Flexible FSP model providing targeted functional services including clinical monitoring, data management, pharmacovigilance, and regulatory support.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-03
Description

Comac Medical Group acquired ILIFE Consulting on June 3, 2025. ILIFE is a specialized CRO headquartered in Paris, France, renowned for expertise in oncology, rare diseases, and complex biotech clinical trials. Founded in 2013 by Marina Iché, ILIFE has built a distinguished reputation for delivering high-value strategic consulting alongside clinical trial execution. The acquisition strengthens Comac Medical's pan-European CRO network with deep expertise in early-phase biotech and oncology research. McDermott Will & Emery advised ILIFE Consulting on the acquisition.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Large global CRO (PE-owned by EQT/Goldman Sachs) covering all phases of clinical development with strong oncology and rare disease franchises. Direct competitor and listed Comac partner/customer.

TypeDirect peer
Description

Biopharma solutions organization offering full-service clinical development and commercial services. Direct competitor for Phase I-IV work and listed as a Comac customer for regional project execution in Europe.

TypeEmerging player
Description

Mid-size CRO with European presence and therapeutic-area focus across oncology and rare diseases. Comparable emerging player competing for similar biotech and mid-pharma sponsors.

TypeEmerging player
Description

Specialized provider of clinical endpoint and data management technology and services for clinical trials. Adjacent competitor in biometrics, eCOA and central lab services where Comac also offers capabilities.

TypeDirect peer
Description

Largest global CRO with comprehensive clinical, data and technology offerings. Direct competitor for enterprise pharma contracts and listed as both customer and competitor in Comac's ecosystem, illustrating the prime/subcontractor dynamic.

TypeDirect peer
Description

Mid-size global CRO with strong specialty therapeutic focus including oncology, rare disease and CNS. Highly comparable to Comac's post-ILIFE positioning as a flexible, science-led alternative to mega-CROs.

TypeBroad incumbent
Description

Thermo Fisher-owned global CRO providing comprehensive clinical development and laboratory services. Operates broadly across all therapeutic areas and geographies; listed as a Comac customer for regional execution.

TypeDirect peer
Description

Global full-service CRO offering Phase I-IV clinical trial management, FSP, biometrics and laboratory services across all major geographies. Direct competitor to Comac for Big Pharma and biotech trial awards, and simultaneously a Comac customer/partnership counterparty.

TypeDirect peer
Description

Mid-to-large full-service CRO focused on small and mid-sized biopharma, with deep therapeutic-area expertise. Closest comparable in size and operating model to Comac, particularly following the ILIFE acquisition that mirrors Medpace's biotech specialization.

TypeBroad incumbent
Description

Major preclinical and clinical CRO with deep laboratory and early-phase capabilities. Overlaps with Comac's Early Phase Unit and Bioanalytical Lab offering, though primarily positioned upstream in preclinical research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers20 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries13 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Comac Medical

Contract Research Organization (CRO) Servicescomac-medical.com

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) headquartered in Bulgaria, delivering Phase I-IV clinical trials, bioanalytical, and FSP services to pharmaceutical, biotech, and CRO clients across 24+ countries.

What Comac Medical does

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) headquartered in Sofia, Bulgaria, delivering clinical trial services from Phase I through Phase IV, including post-marketing, medical device, nutraceutical, biosimilar, and generics studies. The company was founded in 1998 and operates across 24+ countries with 350+ employees, leveraging a fully owned, Europe-based Early Phase Clinical Research Unit and an in-house GCLP-accredited Bioanalytical Laboratory. Its customer base spans major pharmaceutical companies, biotechnology firms, and other CROs, and it is recognized as a Top 10 CRO in Europe.

The company's service portfolio is organized into integrated solutions and services covering early phase trials, late phase trials, post-marketing studies, medical devices and nutraceuticals, and biosimilars/generics, supported by a Functional Service Provider (FSP) offering for flexible resourcing. Comac monetizes through quote-based, project-priced professional services engagements on multi-year contracts, sold through a direct enterprise sales motion supplemented by heavy participation in industry conferences (OCT Europe, Swiss Biotech Day, BioEurope, ASCO, ESMO). Comac holds ISO 9001:2015 certification, GCLP laboratory accreditation, French Ministry R&D approval, and has received FDA No Action Indicated (NAI) inspection letters.

In June 2023, Edgecap acquired a majority stake while founder Milen Vrabevski and management retained a meaningful minority. The company has since professionalized its executive team, appointing a new Group CEO, CFO, COO, and CCO, and in June 2025 acquired ILIFE Consulting, a Paris-based specialty CRO focused on oncology, rare diseases, and complex biotech trials. The combined platform is positioned as a flexible, cost-efficient boutique alternative to large global CROs, with deep Central and Eastern European reach and growing Western European and US presence.

Comac Medical firmographics

Firmographics
Name
Comac Medical
Legal name
Comac Medical Ltd.
Website
https://comac-medical.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
101–250 employees
Short description
Comac Medical is a pan-European, full-service Contract Research Organization (CRO) headquartered in Bulgaria, delivering Phase I-IV clinical trials, bioanalytical, and FSP services to pharmaceutical, biotech, and CRO clients across 24+ countries.
Ownership category
akta.pro rank

Comac Medical industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Clinical trial services
  • Contract research organization
  • Early phase trials
  • Functional service provider
  • Biopharma clinical research

Where Comac Medical is headquartered

Location

Headquarters

HQ city
Sofia
HQ country
Bulgaria
HQ region
Europe

Offices14 records

Markets served

Comac Medical business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. CRO Services - Clinical Trial Management: Full-service Contract Research Organization services managing clinical trials from Phase I through Phase IV, including project management, monitoring, data management, and regulatory affairs
  2. Early Phase Clinical Research Unit: Dedicated early phase clinical trial unit providing first-in-human and proof-of-concept studies for pharmaceutical and biotech sponsors
  3. Functional Service Provider (FSP): Flexible staffing and functional service solutions providing dedicated resources or functional support to sponsors
  4. Medical Devices & Nutraceuticals: Clinical investigation services for medical devices and food supplements/nutraceuticals
  5. Biosimilar & Generics Development: Clinical development services specifically designed for biosimilar and generic pharmaceutical products

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing tailored to sponsor requirements

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Comac Medical product offering

Product offering

Core offering

Comac Medical is a full-service Pan-European Contract Research Organization (CRO) delivering clinical trial solutions from Phase I through Phase IV. Its offering spans early-phase clinical trials, late-phase trials, post-marketing trials, medical device and nutraceutical investigations, and biosimilar/generics development, supported by a Europe-based fully owned Early Phase Clinical Research Unit and in-house Bioanalytical Lab. It also provides Functional Service Provider (FSP) and dedicated resource/consulting services to pharmaceutical, biotech, and other CRO clients across 24+ countries.

Product overview

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) offering an integrated portfolio of clinical trial solutions spanning early phase (Phase I-II), late phase (Phase III-IV), post-marketing trials, medical devices, and biosimilar/generics services. The core offering is organized around Solutions (Early Phase Clinical Trials, Late Phase Clinical Trials, Post Marketing Trials, Medical Devices & Nutraceuticals, Biosimilar & Generics) and Services (CRO Services, Early Phase Clinical Research Unit, and Functional Service Provider). The company also maintains a fully owned Europe-based Early Phase Unit and Bioanalytical Lab, supporting end-to-end trial delivery from a single platform.

Differentiator

Problem solved

Functional benefit

Brands

  • ILIFE Consulting: Specialized CRO headquartered in Paris, France, renowned for expertise in oncology, rare diseases, and complex biotech clinical trials. Founded in 2013 by Marina Iché.

Products and services

  • Early Phase Clinical Trials Comprehensive Phase I-II early phase clinical trial solutions leveraging a Europe-based fully owned Early Phase Unit and Bioanalytical Lab, tailored for biotech and complex clinical studies including oncology and rare diseases.
  • Late Phase Clinical Trials Full-service Phase III-IV late phase clinical trial management and execution across diverse European regions.
  • Post Marketing Trials Post-marketing surveillance and observational trial services supporting product lifecycle management.
  • Medical Devices & Nutraceuticals Clinical investigation services for medical devices and food supplements, covering regulatory and execution needs.
  • Biosimilar & Generics Specialized clinical trial services for biosimilar and generic pharmaceutical products.
  • Contract Research Organization (CRO) Services Full-service CRO services covering study design, project management, site monitoring, data management, and regulatory affairs across all trial phases.
  • Early Phase Clinical Research Unit Europe-based, fully owned early phase clinical research unit and bioanalytical laboratory, combining long-term expertise with cutting-edge facilities in one location; operates 2 Early Phase Unit locations.
  • Functional Service Provider (FSP) Flexible FSP model providing targeted functional services including clinical monitoring, data management, pharmacovigilance, and regulatory support.

Quantifiable outcome

  • Industry-leading speed in patient recruitment, site access, and retention
  • +3 more outcomes

Companies that use Comac Medical

Customer profile

Named customers20 records

Segments3 records

Ideal customer profiles3 records

Comac Medical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Comac Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ILIFE ConsultingcoreStrategic or Co-development Partner · 3 June 2025Comac Medical Group acquired ILIFE Consulting on June 3, 2025. ILIFE is a specialized CRO headquartered in Paris, France, renowned for expertise in oncology, rare diseases, and complex biotech clinical trials. Founded in 2013 by Marina Iché, ILIFE has built a distinguished reputation for delivering high-value strategic consulting alongside clinical trial execution. The acquisition strengthens Comac Medical's pan-European CRO network with deep expertise in early-phase biotech and oncology research. McDermott Will & Emery advised ILIFE Consulting on the acquisition.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Comac Medical competitors and assessment

Company assessment

Direct peers

  • Parexel International: Large global CRO (PE-owned by EQT/Goldman Sachs) covering all phases of clinical development with strong oncology and rare disease franchises. Direct competitor and listed Comac partner/customer.
  • Syneos Health: Biopharma solutions organization offering full-service clinical development and commercial services. Direct competitor for Phase I-IV work and listed as a Comac customer for regional project execution in Europe.
  • IQVIA: Largest global CRO with comprehensive clinical, data and technology offerings. Direct competitor for enterprise pharma contracts and listed as both customer and competitor in Comac's ecosystem, illustrating the prime/subcontractor dynamic.
  • Worldwide Clinical Trials: Mid-size global CRO with strong specialty therapeutic focus including oncology, rare disease and CNS. Highly comparable to Comac's post-ILIFE positioning as a flexible, science-led alternative to mega-CROs.
  • ICON plc: Global full-service CRO offering Phase I-IV clinical trial management, FSP, biometrics and laboratory services across all major geographies. Direct competitor to Comac for Big Pharma and biotech trial awards, and simultaneously a Comac customer/partnership counterparty.
  • Medpace Holdings: Mid-to-large full-service CRO focused on small and mid-sized biopharma, with deep therapeutic-area expertise. Closest comparable in size and operating model to Comac, particularly following the ILIFE acquisition that mirrors Medpace's biotech specialization.

Emerging players

  • Clinipace Worldwide: Mid-size CRO with European presence and therapeutic-area focus across oncology and rare diseases. Comparable emerging player competing for similar biotech and mid-pharma sponsors.
  • Clario: Specialized provider of clinical endpoint and data management technology and services for clinical trials. Adjacent competitor in biometrics, eCOA and central lab services where Comac also offers capabilities.

Broad incumbents

  • PPD (Thermo Fisher Scientific): Thermo Fisher-owned global CRO providing comprehensive clinical development and laboratory services. Operates broadly across all therapeutic areas and geographies; listed as a Comac customer for regional execution.
  • Charles River Laboratories: Major preclinical and clinical CRO with deep laboratory and early-phase capabilities. Overlaps with Comac's Early Phase Unit and Bioanalytical Lab offering, though primarily positioned upstream in preclinical research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Comac Medical social profiles

Digital presence

Comac Medical compliance and trust

Trust signal

Compliance5 records

Comac Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Comac Medical leadership team

Management profile

Number of profiles

Profiles14 records

Comac Medical subsidiaries and ownership

Company hierarchy

Subsidiaries13 records

Comac Medical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Comac Medical M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Comac Medical

What does Comac Medical do?

Comac Medical is a full-service Pan-European Contract Research Organization (CRO) delivering clinical trial solutions from Phase I through Phase IV. Its offering spans early-phase clinical trials, late-phase trials, post-marketing trials, medical device and nutraceutical investigations, and biosimilar/generics development, supported by a Europe-based fully owned Early Phase Clinical Research Unit and in-house Bioanalytical Lab. It also provides Functional Service Provider (FSP) and dedicated resource/consulting services to pharmaceutical, biotech, and other CRO clients across 24+ countries.

Is Comac Medical a public or private company?

Comac Medical is a private company. It is classified as private equity controlled and is currently operating.

When was Comac Medical founded?

Comac Medical was founded in 1998. It employs 101 to 250 people.

Where is Comac Medical based?

Comac Medical is headquartered in Sofia, Bulgaria, in the Europe region.

How does Comac Medical make money?

Five revenue lines are on record. CRO Services - Clinical Trial Management is the primary driver. The others are early Phase Clinical Research Unit, functional Service Provider (FSP), medical Devices & Nutraceuticals and biosimilar & Generics Development.

Who are Comac Medical's main competitors?

Direct peers on record are Parexel International, Syneos Health, IQVIA, Worldwide Clinical Trials, ICON plc and Medpace Holdings. Emerging players are Clinipace Worldwide and Clario. Broad incumbents are PPD (Thermo Fisher Scientific) and Charles River Laboratories.

Does Comac Medical have an API?

No public API is recorded for Comac Medical.

What industry is Comac Medical in?

Comac Medical's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireInnovative Drug CRO Market to Soar USD 96.06 Billion by 2035, Expanding at 5.44% CAGRThe global innovative drug Contract Research Organization (CRO) market is projected to grow from USD 59.63 billion in 2026 to USD 96.06 billion by 2035, expanding at a compound annual growth rate of 5.44%. This expansion is primarily driven by increasing R&D costs, rising clinical trial complexities, and the growing demand for specialized services in oncology and rare diseases. Key industry developments include strategic acquisitions by firms such as ACL Digital and Comac Medical Group to enhance service capabilities.The Manila TimesEdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CROComac Medical Group, backed by EdgeCap Partners, acquired ILIFE Consulting, a Paris-based CRO specializing in oncology and early-phase biotech trials. The deal expands the Group's pan-European footprint and adds expertise in biostatistics, data management, and pharmacovigilance. ILIFE's founder Marina Iché will remain CEO and become a significant shareholder.PR NewswireEdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CROComac Medical Group, backed by EdgeCap Partners, acquired ILIFE Consulting, a Paris-based CRO specializing in oncology and early-phase biotech trials. The deal expands the Group's pan-European footprint and adds expertise in biostatistics, data management, and pharmacovigilance. ILIFE's founder Marina Iché will remain CEO and become a significant shareholder.The Globe and MailEdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CROEdgeCap-backed Comac Medical Group acquired ILIFE Consulting, a French early-phase specialty CRO. The strategic acquisition aims to establish a pan-European footprint and deepen expertise in oncology and early-phase biotech clinical trials.PR NewswireComac Medical Announces New Leadership Appointments and International ExpansionComac Medical appointed Dr. Chris Smyth as CEO and established a Supervisory Board chaired by Neil Ferguson. The company is expanding internationally with local entities in the US, Germany, and the UK, aiming to become the leading pan-European CRO for biotech and biopharma.CrosstreecapitalPharma Services Blue Book June 2023The June 2023 BlueBook Pharma Services report details key mergers and acquisitions in the health sciences sector, including Biocomputing Platforms Ltd.'s acquisition of Oy 4Pharma Ltd. and EdgeCap Partners OU's acquisition of Comac Medical Ltd. Additionally, the article highlights Beaconcure Inc.'s completion of a $14 million Series A financing led by NewVale Capital LLC.PR NewswireEdgeCap acquires majority stake in Comac Medical, founder and management retain significant minority interestEdgeCap Partners acquired a majority equity stake in Comac Medical, with founder Dr. Milen Vrabevski and other shareholders retaining significant minority interests while continuing in their executive roles. The transaction, completed in June 2023, aims to accelerate Comac's organic growth and drive consolidation within the clinical research organization (CRO) sector through a buy-and-build strategy. Financial terms of the deal were not disclosed.NewswireEdgeCap acquires majority stake in Comac Medical, founder and management retain significant minority interestEdgeCap Partners has acquired a majority equity interest in Comac Medical, which is a leading full-service clinical research organization in Southeastern Europe, as announced on June 9, 2023. The founder and CEO, Dr. Milen Vrabevski, and other shareholders will retain a significant minority stake while continuing to manage the company. The acquisition is expected to support Comac Medical's growth and expansion in the healthcare and life sciences sectors.PR NewswireEdgeCap acquires majority stake in Comac Medical, founder and management retain significant minority interestEdgeCap Partners has acquired a majority equity stake in Comac Medical, with the company's founder and CEO Dr. Milen Vrabevski retaining a significant minority interest and continuing in his executive role. The transaction, completed in June 2023, aims to accelerate Comac Medical's growth and drive consolidation in the clinical research organization (CRO) sector through a buy-and-build strategy. Financial terms of the deal were not disclosed.PR NewswireEdgeCap acquiert une participation majoritaire dans Comac Medical, le fondateur conservant une participation minoritaire significativeEdgeCap Partners has acquired a majority stake in Comac Medical, with Comac's founder Dr. Milen Vrabevski retaining a significant minority ownership. This acquisition is viewed as a significant step for Comac Medical and aims to enhance its growth trajectory in the clinical research organization market. The transaction was finalized in June 2023, with financial details undisclosed.